NCT04677608 (ASPYRE-1) is a clinical trial in Pulmonary Arterial Hypertension, sponsored by iPHNET (italian Pulmonary Hypertension NETwork).

Who is sponsoring NCT04677608?

NCT04677608 is sponsored by iPHNET (italian Pulmonary Hypertension NETwork).

What condition does NCT04677608 study?

NCT04677608 studies Pulmonary Arterial Hypertension.

Is NCT04677608 still recruiting?

NCT04677608 is currently status unknown. Last updated 21 December 2020.

Last reviewed 2020-12-21 · How we verify

NCT04677608: ASPYRE-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk Score

Status unknown Last updated 21 December 2020

What this trial tests

trial in Pulmonary Arterial Hypertension in 500 participants. Status unknown.

Timeline

21 July 2020

Primary endpoint
30 April 2021

31 August 2022

Quick facts

Lead sponsor	iPHNET (italian Pulmonary Hypertension NETwork)
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	21 July 2020
Primary completion	30 April 2021
Estimated completion	31 August 2022
Sites	1 location across Italy

Conditions studied

Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →

Sponsor

iPHNET (italian Pulmonary Hypertension NETwork)

Who can join

Adults 18 to 85, any sex, with Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pulmonary Arterial Hypertension (PAH) is a chronic disease characterized by a progressive increase in pulmonary vascular resistance (PVR), which leads to right ventricular (RV) failure, and ultimately death. Different studies have outlined how various factors as vascular resistance, functional class, age, correlate with mortality. However, the modality of death and risk factors for mortality in patients with PAH are little known. For this purpose, more studies are necessary to analyze the risk factors related to modality of death in PAH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pulmonary Arterial Hypertension

Currently open trials in the same condition.

NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) · active not recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension · recruiting
NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting

Other iPHNET (italian Pulmonary Hypertension NETwork) trials

Trials by the same sponsor.

NCT04681014 — CTEPH in Patients With Prior Pulmonary Embolism and Risk Score Validation · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04677608 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by iPHNET (italian Pulmonary Hypertension NETwork)
Last refreshed: 21 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04677608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing